CatalYm to present data on targeting novel checkpoint GDF-15 for immunotherapy of cancer at AACR Annual Meeting

19 June 2020

CatalYm will be presenting two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralisation by CTL-002 antibody in cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on 22-24 June.

Tumor-derived GDF-15 suppresses T-lymphocyte recruitment to the tumor microenvironment describes in vitro and in vivo data, which demonstrate that tumour cells secrete GDF-15 to block T-cell entry into tumour tissue. Neutralising GDF-15 with CatalYm‘s proprietary antibody (CTL-002) restored the ability of CD8+ T-cells to enter the tumour.

 

Identifying GDF-15 as potential novel immunotherapeutic target linked to immune cellexclusion in tumors and resistance to anti-PD-1 treatment reveals that melanoma patients with high GDF-15 levels have significantly shorter survival and are less likely to respond to anti-PD1 therapy. In addition, intratumoral GDF-15 levels in human melanoma correlated inversely with CD3+ and CD8+ T cell infiltration. Consequently, GDF-15 may serve as a predictive biomarker for anti-PD1 response and potentially represents a novel target in the immunotherapy of cancer to improve tumour immune cell infiltration and response to cancer immunotherapy.

 

Dr. Manfred Rüdiger, CEO of CatalYm, said: “Our data shows that GDF-15 is a novel checkpoint factor secreted by tumours. GDF-15 serves as T cell repellent and may cause low or no response to modern immunotherapies. Neutralising GDF-15 with our CTL-002 antibody is a novel promising approach to increase response rates of cancer immunotherapies and overall survival of cancer patients.”

CTL-002 is set to enter clinical development during 2020.

Image credit: Bogomil Mihaylor

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free